Surgery Partners, Inc. Announces Second Quarter 2025 Results
Surgery Partners (NASDAQ:SGRY) reported strong Q2 2025 financial results, with revenue increasing 8.4% to $826.2 million and Adjusted EBITDA growing 9.0% to $129.0 million. Same-facility revenues rose 5.1%, driven by a 3.4% increase in cases and 1.6% growth in revenue per case.
The company reaffirmed its full-year 2025 guidance, projecting revenue between $3.30-3.45 billion and Adjusted EBITDA of $555-565 million. Surgery Partners maintained strong liquidity with $250.1 million in cash and $394.9 million available under its revolving credit facility, while operating cash flow was $81.3 million for Q2 2025.
Surgery Partners (NASDAQ:SGRY) ha riportato solidi risultati finanziari per il secondo trimestre del 2025, con un fatturato in crescita dell'8,4% a 826,2 milioni di dollari e un EBITDA rettificato aumentato del 9,0% a 129,0 milioni di dollari. I ricavi delle strutture esistenti sono aumentati del 5,1%, grazie a un incremento del 3,4% dei casi trattati e a una crescita dell'1,6% del ricavo per caso.
L'azienda ha confermato le previsioni per l'intero anno 2025, prevedendo un fatturato compreso tra 3,30 e 3,45 miliardi di dollari e un EBITDA rettificato tra 555 e 565 milioni di dollari. Surgery Partners ha mantenuto una solida liquidità con 250,1 milioni di dollari in contanti e 394,9 milioni di dollari disponibili tramite la linea di credito revolving, mentre il flusso di cassa operativo è stato di 81,3 milioni di dollari nel secondo trimestre del 2025.
Surgery Partners (NASDAQ:SGRY) reportó sólidos resultados financieros en el segundo trimestre de 2025, con ingresos que aumentaron un 8,4% hasta los 826,2 millones de dólares y un EBITDA ajustado que creció un 9,0% hasta los 129,0 millones de dólares. Los ingresos en las mismas instalaciones aumentaron un 5,1%, impulsados por un incremento del 3,4% en los casos y un crecimiento del 1,6% en los ingresos por caso.
La compañía reafirmó su guía para todo el año 2025, proyectando ingresos entre 3,30 y 3,45 mil millones de dólares y un EBITDA ajustado de 555 a 565 millones de dólares. Surgery Partners mantuvo una fuerte liquidez con 250,1 millones de dólares en efectivo y 394,9 millones de dólares disponibles bajo su línea de crédito revolvente, mientras que el flujo de caja operativo fue de 81,3 millones de dólares en el segundo trimestre de 2025.
Surgery Partners (NASDAQ:SGRY)는 2025년 2분기 강력한 재무 실적을 발표했으며, 매출은 8.4% 증가한 8억 2,620만 달러, 조정 EBITDA는 9.0% 증가한 1억 2,900만 달러를 기록했습니다. 동일 시설 매출은 5.1% 증가했으며, 이는 케이스 수 3.4% 증가와 케이스당 매출 1.6% 증가에 기인합니다.
회사는 2025년 전체 가이던스를 재확인하며, 매출을 33억~34억 5천만 달러, 조정 EBITDA를 5억 5,500만~5억 6,500만 달러로 전망했습니다. Surgery Partners는 2억 5,010만 달러의 현금과 3억 9,490만 달러의 회전 신용 한도를 보유하며 강력한 유동성을 유지했으며, 2025년 2분기 영업 현금 흐름은 8,130만 달러였습니다.
Surgery Partners (NASDAQ:SGRY) a publié de solides résultats financiers pour le deuxième trimestre 2025, avec un chiffre d'affaires en hausse de 8,4 % à 826,2 millions de dollars et un EBITDA ajusté en croissance de 9,0 % à 129,0 millions de dollars. Les revenus des établissements existants ont augmenté de 5,1 %, grâce à une hausse de 3,4 % du nombre de cas et une croissance de 1,6 % du revenu par cas.
La société a confirmé ses prévisions pour l'ensemble de l'année 2025, prévoyant un chiffre d'affaires compris entre 3,30 et 3,45 milliards de dollars et un EBITDA ajusté entre 555 et 565 millions de dollars. Surgery Partners a maintenu une solide liquidité avec 250,1 millions de dollars en liquidités et 394,9 millions de dollars disponibles sur sa ligne de crédit renouvelable, tandis que le flux de trésorerie opérationnel s'est élevé à 81,3 millions de dollars pour le deuxième trimestre 2025.
Surgery Partners (NASDAQ:SGRY) meldete starke Finanzergebnisse für das zweite Quartal 2025, mit einem Umsatzanstieg von 8,4 % auf 826,2 Millionen US-Dollar und einem um 9,0 % auf 129,0 Millionen US-Dollar gestiegenen bereinigten EBITDA. Die Umsätze in bestehenden Einrichtungen stiegen um 5,1 %, was auf einen Anstieg der Fallzahlen um 3,4 % und einen Umsatzanstieg pro Fall um 1,6 % zurückzuführen ist.
Das Unternehmen bestätigte seine Prognose für das Gesamtjahr 2025 und erwartet einen Umsatz zwischen 3,30 und 3,45 Milliarden US-Dollar sowie ein bereinigtes EBITDA von 555 bis 565 Millionen US-Dollar. Surgery Partners behielt eine starke Liquidität mit 250,1 Millionen US-Dollar in bar und 394,9 Millionen US-Dollar verfügbarer revolvierender Kreditlinie bei, während der operative Cashflow im zweiten Quartal 2025 81,3 Millionen US-Dollar betrug.
- Revenue growth of 8.4% year-over-year to $826.2 million
- Adjusted EBITDA increased 9.0% to $129.0 million
- Same-facility cases grew 3.4% with 5.1% revenue increase
- Strong liquidity position with $645 million in combined cash and credit facility availability
- Net loss of $2.5 million in Q2 2025
- Operating cash flow declined from $123.5M to $87.3M year-to-date
- High leverage ratio of 4.7x (consolidated debt/Adjusted EBITDA)
- Increased cash interest payments impacting cash flow
Insights
Surgery Partners reports solid Q2 with 8.4% revenue growth and 9% EBITDA growth, reaffirming 2025 guidance despite small net loss.
Surgery Partners delivered a solid second quarter with revenue increasing
While the company posted a modest net loss of
The company maintains a reasonably strong liquidity position with
The slight decline in operating cash flow (
Management's reaffirmation of full-year guidance (
Reaffirms Full Year 2025 Guidance
BRENTWOOD, Tenn., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced results for the second quarter ended June 30, 2025.
Second Quarter 2025 Financial Highlights
(All comparisons are year-over-year unless otherwise noted)
- Revenue increased
8.4% for the second quarter- Same-facility revenues increased
5.1% for the second quarter - Same-facility cases increased
3.4% for the second quarter
- Same-facility revenues increased
- Net loss attributable to Surgery Partners, Inc. was
$2.5 million for the second quarter- Adjusted EBITDA increased
9.0% to$129.0 million for the second quarter
- Adjusted EBITDA increased
2025 Guidance
- Full year 2025 revenue and Adjusted EBITDA guidance reaffirmed to be in the range of
$3.30 billion to$3.45 billion and$555 million to$565 million , respectively
Eric Evans, Chief Executive Officer, stated, “We are proud to report strong growth in Adjusted EBITDA and revenue, demonstrating the strength of our operational strategy as we capitalize on the continued momentum in the ambulatory surgery industry. Our continued focus on maximizing portfolio performance, optimistic outlook on surgical trends and regulatory landscape, and focus on exceptional clinical quality and value, positions us for continued growth in 2025 and beyond. Our growth is the result of a relentless focus on excellence and differentiation in our core short-stay surgical service lines. In line with our commitment to enhance shareholder value, we are actively evaluating portfolio optimization opportunities to expedite leverage reduction, accelerate cash flow generation and provide increased flexibility to self-fund our growth algorithm following the conclusion of the recent strategic process.”
Dave Doherty, Chief Financial Officer, commented, “The results we report today are very much aligned with our internal expectations and give us confidence in reaffirming our guidance for the full year. Our guidance implies continued margin expansion, reflecting our on-going operating system improvements as well as the integration benefits from recent acquisitions and contributions from de novos we expect to open this year.”
Second Quarter 2025 Results
Revenues for the second quarter of 2025 increased
Year-to-Date 2025 Results
Revenues year-to-date 2025 increased
Liquidity
Surgery Partners had cash and cash equivalents of
Year-to-date, operating cash flows were
The Company’s ratio of total net debt to EBITDA, as calculated under the Company’s credit agreement, was approximately 4.1x at the end of the second quarter of 2025. Leverage calculated using consolidated debt from our balance sheet divided by Adjusted EBITDA, before reducing it for NCI, was 4.7x times.
Conference Call Information
Surgery Partners will hold a conference call today, August 5, 2025 at 8:30 a.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-844-826-3033, or for international callers, 1-412-317-5185. A replay will be available three hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 10201328. The replay will be available until August 19, 2025.
Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company's website at www.surgerypartners.com. The replay will also be available on this same website for a limited time following the call.
To learn more about Surgery Partners, please visit the Company's website at www.surgerypartners.com. Surgery Partners uses its website as a channel of distribution for material Company information. Financial and other material information regarding Surgery Partners is routinely posted on the Company's website and is readily accessible.
About Surgery Partners
Headquartered in Brentwood, Tennessee, Surgery Partners is a leading healthcare services company with a differentiated outpatient delivery model focused on providing high quality, cost effective solutions for surgical and related ancillary care in support of both patients and physicians. Founded in 2004, Surgery Partners is one of the largest and fastest growing surgical services businesses in the country, with more than 200 locations in 30 states, including ambulatory surgery centers, surgical hospitals, multi-specialty physician practices and urgent care facilities. For additional information, visit www.surgerypartners.com.
Forward-Looking Statements
This press release contains forward-looking statements, including those regarding growth, our anticipated operating results for future periods and other similar statements. These statements can be identified by the use of words such as "believes," "anticipates," "expects," "intends," "plans," "continues," "estimates," "predicts," "projects," "forecasts," "may," "could," and similar expressions. All forward-looking statements are based on current expectations and beliefs as of the date of this release and are subject to risks, uncertainties and other factors that may cause actual results to differ materially from the expectations discussed in, or implied by, the forward-looking statements. Many of these factors are beyond our ability to control or predict including, without limitation, reductions in payments from government health care programs and private insurance payors, such as health maintenance organizations, preferred provider organizations, and other managed care organizations and employers; our ability to contract with private insurance payors; changes in our payor mix or surgical case mix; failure to maintain or develop relationships with physicians on beneficial or favorable terms, or at all; the impact of payor controls designed to reduce the number of surgical procedures; our efforts to integrate operations of acquired or developed businesses and surgical facilities, attract new physician partners, or acquire additional surgical facilities; supply chain issues, including shortages or quality control issues with surgery-related products, equipment and medical supplies; competition for physicians, nurses, strategic relationships, acquisitions and managed care contracts; our ability to attract and retain qualified health care professionals; our ability to enforce non-compete restrictions against our physicians; our ability to manage material liabilities whether known or unknown incurred as a result of acquiring or operating surgical facilities; the impact of future legislation and other health care regulatory reform actions, and the effect of that legislation and other regulatory actions on our business; our ability to comply with current health care laws and regulations; the outcome of legal and regulatory proceedings that have been or may be brought against us; the impact of cybersecurity attacks or intrusions, changes in the regulatory, economic and other conditions of the states where our surgical facilities are located; our indebtedness; the social and economic impact of a pandemic, epidemic or outbreak of a contagious disease on our business; and the risks and uncertainties identified and discussed from time to time in the Company’s reports filed with the SEC, including in Item 1A under the heading "Risk Factors" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and other reports filed with the SEC. Except as required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements to reflect events or circumstances after the date of this report, or to reflect the occurrence of unanticipated events or circumstances.
Use of Non-GAAP Financial Measures
In addition to the results prepared in accordance with generally accepted accounting principles in the United States ("GAAP") provided throughout this press release, Surgery Partners has presented the following non-GAAP financial measures: Adjusted net income (loss) attributable to common stockholders, Adjusted net income (loss) per share attributable to common stockholders, Adjusted EBITDA, and Adjusted EBITDA related to unconsolidated affiliates, which exclude various items detailed in the "Reconciliation of Non-GAAP Financial Measures" below.
These non-GAAP financial measures are not intended to replace financial performance measures determined in accordance with GAAP. Rather, they are presented as supplemental measures of the Company's performance that management believes may enhance the evaluation of the Company's ongoing operating results. These non-GAAP financial measures are not presented in accordance with GAAP, and the Company’s computation of these non-GAAP financial measures may vary from similar measures used by other companies. These measures have limitations as an analytical tool and should not be considered in isolation or as a substitute or alternative to revenue, net income or loss, operating income or loss, cash flows from operating activities, total indebtedness or any other measures of operating performance, liquidity or indebtedness derived in accordance with GAAP.
| SURGERY PARTNERS, INC. Selected Consolidated Financial Data (Dollars in millions, except per share amounts, shares in thousands) (Unaudited) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenues | $ | 826.2 | $ | 762.1 | $ | 1,602.2 | $ | 1,479.5 | ||||||||
| Operating expenses: | ||||||||||||||||
| Salaries and benefits | 235.2 | 223.2 | 473.8 | 438.4 | ||||||||||||
| Supplies | 215.0 | 199.7 | 430.8 | 388.5 | ||||||||||||
| Professional and medical fees | 102.1 | 92.4 | 197.4 | 175.0 | ||||||||||||
| Lease expense | 22.9 | 22.2 | 43.7 | 43.6 | ||||||||||||
| Other operating expenses | 55.4 | 45.4 | 99.0 | 99.5 | ||||||||||||
| Cost of revenues | 630.6 | 582.9 | 1,244.7 | 1,145.0 | ||||||||||||
| General and administrative expenses | 36.1 | 40.3 | 72.1 | 73.5 | ||||||||||||
| Depreciation and amortization | 40.3 | 34.8 | 76.6 | 68.5 | ||||||||||||
| Transaction and integration costs | 18.1 | 19.3 | 42.8 | 36.7 | ||||||||||||
| Net (gain) loss on disposals, consolidations and deconsolidations | (3.0 | ) | 5.3 | 3.4 | 6.8 | |||||||||||
| Equity in earnings of unconsolidated affiliates | (5.5 | ) | (4.4 | ) | (11.1 | ) | (7.1 | ) | ||||||||
| Litigation settlement | — | 0.5 | 2.2 | (1.3 | ) | |||||||||||
| Loss on debt extinguishment | — | 5.1 | — | 5.1 | ||||||||||||
| Other income, net | (2.1 | ) | (6.5 | ) | (2.1 | ) | (8.5 | ) | ||||||||
| 714.5 | 677.3 | 1,428.6 | 1,318.7 | |||||||||||||
| Operating income | 111.7 | 84.8 | 173.6 | 160.8 | ||||||||||||
| Interest expense, net | (67.9 | ) | (51.5 | ) | (130.1 | ) | (98.8 | ) | ||||||||
| Income before income taxes | 43.8 | 33.3 | 43.5 | 62.0 | ||||||||||||
| Income tax benefit (expense) | 1.1 | (4.9 | ) | 1.1 | (9.3 | ) | ||||||||||
| Net income | 44.9 | 28.4 | 44.6 | 52.7 | ||||||||||||
| Less: Net income attributable to non-controlling interests | (47.4 | ) | (43.9 | ) | (84.8 | ) | (80.6 | ) | ||||||||
| Net loss attributable to Surgery Partners, Inc. | $ | (2.5 | ) | $ | (15.5 | ) | $ | (40.2 | ) | $ | (27.9 | ) | ||||
| Net loss per share attributable to common stockholders | ||||||||||||||||
| Basic | $ | (0.02 | ) | $ | (0.12 | ) | $ | (0.32 | ) | $ | (0.22 | ) | ||||
| Diluted(1) | $ | (0.02 | ) | $ | (0.12 | ) | $ | (0.32 | ) | $ | (0.22 | ) | ||||
| Weighted average common shares outstanding | ||||||||||||||||
| Basic | 126,980 | 126,134 | 126,792 | 126,053 | ||||||||||||
| Diluted(1) | 126,980 | 126,134 | 126,792 | 126,053 | ||||||||||||
(1) The impact of potentially dilutive securities for all periods was not considered because the effect would be anti-dilutive.
| SURGERY PARTNERS, INC. Selected Financial and Operating Data (Dollars in millions, except per case and per share amounts) (Unaudited) | ||||||
| June 30, 2025 | December 31, 2024 | |||||
| Balance Sheet Data (at period end): | ||||||
| Cash and cash equivalents | $ | 250.1 | $ | 269.5 | ||
| Total current assets | 1,105.3 | 1,119.4 | ||||
| Total assets | 7,954.8 | 7,890.0 | ||||
| Current maturities of long-term debt | 110.0 | 101.4 | ||||
| Total current liabilities | 573.3 | 624.4 | ||||
| Long-term debt, less current maturities | 3,465.2 | 3,268.9 | ||||
| Total liabilities | 4,375.9 | 4,254.8 | ||||
| Non-controlling interests—redeemable | 422.4 | 438.8 | ||||
| Total Surgery Partners, Inc. stockholders' equity | 1,748.3 | 1,789.7 | ||||
| Non-controlling interests—non-redeemable | 1,408.2 | 1,406.7 | ||||
| Total stockholders' equity | 3,156.5 | 3,196.4 | ||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Cash Flow Data: | ||||||||||||||||
| Net cash provided by (used in): | ||||||||||||||||
| Operating activities | $ | 81.3 | $ | 82.8 | $ | 87.3 | $ | 123.5 | ||||||||
| Investing activities | 2.1 | (244.1 | ) | (74.3 | ) | (327.2 | ) | |||||||||
| Purchases of property and equipment | (23.4 | ) | (26.9 | ) | (46.1 | ) | (47.9 | ) | ||||||||
| Payments for acquisitions, net of cash acquired | (4.0 | ) | (210.0 | ) | (48.0 | ) | (264.6 | ) | ||||||||
| Purchases of equity investments | — | 0.3 | (3.8 | ) | (1.7 | ) | ||||||||||
| Financing activities | (62.6 | ) | 189.6 | (32.4 | ) | 221.3 | ||||||||||
| Distributions to non-controlling interest holders | (54.0 | ) | (40.2 | ) | (116.3 | ) | (80.7 | ) | ||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Other Data: | ||||||||||||||||
| Number of surgical facilities as of the end of period | 162 | 167 | 162 | 167 | ||||||||||||
| Number of consolidated surgical facilities as of the end of period | 115 | 127 | 115 | 127 | ||||||||||||
| Cases | 172,858 | 166,520 | 333,158 | 319,912 | ||||||||||||
| Revenue per case | $ | 4,780 | $ | 4,577 | $ | 4,809 | $ | 4,625 | ||||||||
| Adjusted EBITDA(1) | $ | 129.0 | $ | 118.3 | $ | 232.9 | $ | 215.8 | ||||||||
| Adjusted EBITDA margin(2) | 15.6 | % | 15.5 | % | 14.5 | % | 14.6 | % | ||||||||
| Adjusted net income per share attributable to common stockholders - Basic(1) | $ | 0.17 | $ | 0.21 | $ | 0.22 | $ | 0.31 | ||||||||
| Adjusted net income per share attributable to common stockholders - Diluted(1) | $ | 0.17 | $ | 0.21 | $ | 0.21 | $ | 0.31 | ||||||||
(1) A reconciliation of these non-GAAP financial measures appears below.
(2) Defined as Adjusted EBITDA as a % of Revenues.
| SURGERY PARTNERS, INC. Supplemental Information (Dollars in millions, except per case amounts) (Unaudited) | ||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||
| Same-facility Information(1): | ||||||||||||||
| Cases | 183,623 | 177,514 | 348,883 | 335,907 | ||||||||||
| Case growth | 3.4 | % | N/A | 3.9 | % | N/A | ||||||||
| Revenue per case | $ | 4,736 | $ | 4,663 | $ | 4,842 | $ | 4,821 | ||||||
| Revenue per case growth | 1.6 | % | N/A | 0.4 | % | N/A | ||||||||
| Number of work days in the period | 64 | 64 | 127 | 128 | ||||||||||
| Case growth (days adjusted) | 3.4 | % | N/A | 4.7 | % | N/A | ||||||||
| Revenue growth (days adjusted) | 5.1 | % | N/A | 5.1 | % | N/A | ||||||||
(1) Same-facility information includes cases and revenues from our consolidated and non-consolidated surgical facilities (excluding facilities acquired in new markets or divested during the current and prior periods).
SURGERY PARTNERS, INC.
Reconciliation of Non-GAAP Financial Measures
(Dollars in millions, except per share amounts, shares in thousands)
(Unaudited)
The following table reconciles Adjusted EBITDA to income before income taxes in the reported consolidated financial information, the most directly comparable GAAP financial measure:
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Income before income taxes | $ | 43.8 | $ | 33.3 | $ | 43.5 | $ | 62.0 | ||||||||
| Net income attributable to non-controlling interests | (47.4 | ) | (43.9 | ) | (84.8 | ) | (80.6 | ) | ||||||||
| Interest expense, net | 67.9 | 51.5 | 130.1 | 98.8 | ||||||||||||
| Depreciation and amortization | 40.3 | 34.8 | 76.6 | 68.5 | ||||||||||||
| Equity-based compensation expense | 6.8 | 15.1 | 14.4 | 20.0 | ||||||||||||
| Transaction and integration costs(1) | 18.1 | 19.3 | 42.8 | 36.7 | ||||||||||||
| De novo start-up costs | 2.1 | 1.5 | 3.7 | 3.0 | ||||||||||||
| Net (gain) loss on disposals, consolidations and deconsolidations | (3.0 | ) | 5.3 | 3.4 | 6.8 | |||||||||||
| Litigation settlements and other litigation costs(2) | 0.4 | 1.1 | 3.2 | (0.1 | ) | |||||||||||
| Loss on debt extinguishment | — | 5.1 | — | 5.1 | ||||||||||||
| Other | — | (4.8 | ) | — | (4.4 | ) | ||||||||||
| Adjusted EBITDA(3) | $ | 129.0 | $ | 118.3 | $ | 232.9 | $ | 215.8 | ||||||||
(1) For the three months ended June 30, 2025, this amount includes due diligence, transaction and integration costs related to acquisitions (both completed and in the pipeline) and divested facilities (collectively “M&A costs”) of
For the six months ended June 30, 2025, this amount includes M&A costs of
(2) This amount includes a litigation settlement loss of
This amount includes a litigation settlement loss of
(3) We use Adjusted EBITDA as a measure of financial performance. Adjusted EBITDA is a key measure used by management to assess operating performance, make business decisions and allocate resources. Non-controlling interests represent the interests of third parties, such as physicians, and in some cases, healthcare systems that own an interest in surgical facilities that we consolidate for financial reporting purposes. We believe that it is helpful to investors to present Adjusted EBITDA as defined above because it excludes the portion of net income attributable to these third-party interests and clarifies for investors our portion of Adjusted EBITDA generated by our surgical facilities and other operations. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be considered in isolation or as a substitute for net income, operating income or any other measure calculated in accordance with GAAP. The items excluded from Adjusted EBITDA are significant components in understanding and evaluating our financial performance. We believe such adjustments are appropriate, as the magnitude and frequency of such items can vary significantly and are not related to the assessment of normal operating performance. Our calculation of Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies.
The following table provides supplemental information for Adjusted EBITDA related to unconsolidated affiliates:
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||
| Adjusted EBITDA related to unconsolidated affiliates: | |||||||||||
| Management fee revenues(1)(2) | $ | 8.6 | $ | 6.8 | $ | 16.8 | $ | 13.3 | |||
| Equity in earnings of unconsolidated affiliates(2) | 5.5 | 4.4 | 11.1 | 7.1 | |||||||
| Plus: | |||||||||||
| Start-up costs related to unconsolidated de novo surgical facilities(3) | 1.1 | 0.6 | 1.4 | 0.9 | |||||||
| Adjusted EBITDA related to unconsolidated affiliates | $ | 15.2 | $ | 11.8 | $ | 29.3 | $ | 21.3 | |||
(1) Includes management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method and management of surgical facilities in which it does not own an interest. Management fee revenues are included in Revenues on the Consolidated Statements of Operations.
(2) Included as a component of (loss) income before income taxes in the Adjusted EBITDA reconciliation table above.
(3) Included as a component of de novo start-up costs in the Adjusted EBITDA reconciliation table above.
From time to time, the Company incurs certain non-recurring gains or losses that are normally non-operational in nature and management does not consider relevant in assessing its ongoing operating performance. When significant, Surgery Partners’ management and the Company's Board of Directors typically exclude these gains or losses when evaluating the Company’s operating performance and in certain instances when evaluating performance for incentive compensation purposes. Additionally, management believes that certain investors and equity analysts exclude these or similar items when evaluating the Company’s current or future operating performance and in making informed investment decisions regarding the Company. Accordingly, the Company provides adjusted net income attributable to common stockholders and adjusted net income per share attributable to common stockholders as supplements to the comparable GAAP financial measures. Adjusted net income attributable to common stockholders and adjusted net income per share attributable to common stockholders should not be considered measures of financial performance under GAAP, and the items excluded from such measures are significant components in understanding and assessing financial performance. These measures should not be considered in isolation or as an alternative to the comparable GAAP measures as presented in the consolidated financial statements.
The following table reconciles net income (loss) as reflected in the consolidated statements of operations to adjusted net income attributable to common stockholders used to calculate adjusted net income per share attributable to common stockholders:
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Consolidated Statements of Operations Data: | |||||||||||||||
| Net income | $ | 44.9 | $ | 28.4 | $ | 44.6 | $ | 52.7 | |||||||
| Plus (minus): | |||||||||||||||
| Net income attributable to non-controlling interests | (47.4 | ) | (43.9 | ) | (84.8 | ) | (80.6 | ) | |||||||
| Equity-based compensation expense | 6.8 | 15.1 | 14.4 | 20.0 | |||||||||||
| Transaction and integration costs | 18.1 | 19.3 | 42.8 | 36.7 | |||||||||||
| De novo start-up costs | 2.1 | 1.5 | 3.7 | 3.0 | |||||||||||
| Net (gain) loss on disposals, consolidations and deconsolidations | (3.0 | ) | 5.3 | 3.4 | 6.8 | ||||||||||
| Litigation settlements and other litigation costs | 0.4 | 1.1 | 3.2 | (0.1 | ) | ||||||||||
| Loss on debt extinguishment | — | 5.1 | — | 5.1 | |||||||||||
| Other | — | (4.8 | ) | — | (4.4 | ) | |||||||||
| Adjusted net income attributable to common stockholders | $ | 21.9 | $ | 27.1 | $ | 27.3 | $ | 39.2 | |||||||
| Adjusted net income per share attributable to common stockholders | |||||||||||||||
| Basic | $ | 0.17 | $ | 0.21 | $ | 0.22 | $ | 0.31 | |||||||
| Diluted | $ | 0.17 | $ | 0.21 | $ | 0.21 | $ | 0.31 | |||||||
| Weighted average common shares outstanding | |||||||||||||||
| Basic | 126,980 | 126,134 | 126,792 | 126,053 | |||||||||||
| Diluted | 128,038 | 127,296 | 127,911 | 127,359 | |||||||||||
Contact
Surgery Partners Investor Relations
(615) 234-8940
IR@surgerypartners.com
FAQ
What were Surgery Partners' Q2 2025 revenue and growth numbers?
What is SGRY's full-year 2025 financial guidance?
How much cash and credit availability does Surgery Partners have?
What is Surgery Partners' current debt leverage ratio?
How did SGRY's same-facility metrics perform in Q2 2025?
